However, loss of function mutations are observed in other components of PRC2 in MPNST patients and not in EZH2, while, paradoxically, some MPNST overexpress EZH2, suggesting that EZH2 may still have an oncogenic function outside of PRC2 via non-canonical pathways [132]. The gene discussed is EZH2; the disease is malignant peripheral nerve sheath tumor.